DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

06938 RIBOLIFE-B

Closed Add to Porfolio
Index Constituent : None
Major Shareholders LIANG Zicai & Associates (24.24%)
Future Industry Investment Fund (Limited Partnership) (6.89%)
Shanghai Panlin Asset Management Co., Ltd. (5.41%)
Wise Vigour Limited (5.26%)
SASAC of Kunshan (5.11%)		 Sector Health Care & Biotechnology
Web Site http://www.ribolia.com Tel (86 0512) 5701-7817
Email ir@ribolia.com Fax N/A
Related Equities N/A
Principal Activities The Group is dedicated to the discovery, research and development of RNAi technologies and innovative oligonucleotide therapeutics, with a main focus on siRNA drugs for the treatment of liver diseases, cardiovascular diseases, metabolic diseases, and cancer.

Consolidated List of Substantial Shareholders

Name Number of Shares Interested % of Issued Share Capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool

Complete List of Directors

Director's Name Number of Shares Interested % of issued share capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool
Back to Top